|
業務類別
|
Biotechnology |
|
業務概覽
|
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata. |
| 公司地址
| 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247 |
| 電話號碼
| +1 310 618-6994 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.fortebiorx.com |
| 員工數量
| 19 |
| Mr. Antony A. Riley |
Chief Financial Officer |
美元 452.11K |
29/04/2026 |
| Dr. Paul A. Wagner, PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 670.05K |
29/04/2026 |
|
|
| Mr. Shivpreet Singh Kapoor |
Independent Director |
29/04/2026 |
| Mr. Steven Kornfeld |
Independent Director |
29/04/2026 |
| Dr. Paul A. Wagner, PhD |
Chairman of the Board, President and Chief Executive Officer |
29/04/2026 |
| Mr. David W. Gryska, M.B.A. |
Independent Director |
29/04/2026 |
| Dr. Stephen K. Doberstein, PhD |
Independent Director |
29/04/2026 |
| Dr. Barbara K. Finck, M.D. |
Director |
29/04/2026 |
| Mr. Richard G. Vincent |
Independent Director |
29/04/2026 |
| Dr. Scott C. Brun, M.D. |
Independent Director |
29/04/2026 |
|
|
|
|
